CXCL9/10/11-CXCR3 Chemokine-Axis Matching CAR-T Development Service

Enhance CAR-T infiltration and persistence in solid tumors with Creative Biolabs' CXCL9/10/11–CXCR3 Chemokine-Axis Matching CAR-T Development Service. By precisely engineering CAR-T cells to express optimized CXCR3 isoforms, we enable efficient trafficking into "cold" tumor sites driven by the natural CXCL9/10/11 gradient. This targeted chemokine-axis alignment promotes robust immune activation within the tumor microenvironment, transforming non-responsive lesions into immunologically "hot" tumors and supporting more durable and clinically meaningful anti-tumor responses.

Introduction

The CXCR3 chemokine axis is critical for immune cell trafficking, yet its dual role presents a therapeutic challenge. The receptor exists as opposing isoforms: CXCR3-A promotes tumor cell proliferation and metastasis, while CXCR3-B drives apoptosis and recruits anti-tumor lymphocytes to the TME. The key to effective immunotherapy lies in harnessing the CXCL9/10/11 gradient, a marker of IFN-γ-driven immunity, to selectively guide effector cells. This targeted recruitment is the next frontier in improving CAR-T efficacy against solid tumors that lack sufficient T-cell infiltration.

Fig.1 Function of the CXCR3 signaling pathway in the tumor microenvironment.¹

Creative Biolabs' CXCL9/10/11-CXCR3 Chemokine-Axis Matching CAR-T Development Service

The major hurdle in solid tumor CAR-T therapy is the immune-excluded tumor microenvironment where T-cells fail to infiltrate and reach the target antigen. Creative Biolabs solves this fundamental problem by transforming conventional CAR-T cells into "programmable hunters" equipped with the correct homing device: the CXCR3 receptor.

We provide a scientifically grounded, functional solution by engineering your CAR-T cells to effectively read the TME's chemokine signals.

• Enhanced T-Cell Trafficking: We genetically co-express the CXCR3 receptor on your CAR-T cells, ensuring they migrate along the CXCL9/10/11 gradient released by the TME's immune components.
• Immunosuppression Bypass: By concentrating T-cells at the tumor site, our approach helps overcome spatial barriers and increases the local effector-to-target ratio, a critical factor for successful solid tumor clearance.
• Next-Generation CAR-T Construct: We deliver optimized vector designs that co-express the CAR and the homing receptor using multicistronic expression systems, maintaining full CAR-T cell activation and persistence functionality.
• Comprehensive Functional Data: You receive validated evidence of enhanced chemotaxis and target-specific cytotoxicity in both in vitro and relevant in vivo solid tumor models, drastically de-risking your preclinical pipeline.

Discover How We Can Help - Request a Consultation.

What We Can Offer

Creative Biolabs utilizes proprietary, adaptable platforms to execute the precise genetic modification required for chemokine-axis matching. Our services integrate advanced molecular engineering with rigorous functional validation.

Work Process

The required starting materials include tumor biopsy data detailing CXCL9/10/10/11 expression profiles, the target antigen scFv sequence, and patient leukapheresis material for genetic engineering.

The final deliverables comprise a vector plasmid, a comprehensive in vitro data package with chemotaxis and cytotoxicity results, and a preclinical in vivo efficacy report on T-cell persistence and tumor reduction.

Core Benefits

• Precise CXCR3 Targeting: We engineer the CXCR3-B isoform to enhance anti-tumor immune recruitment while avoiding pro-tumor signaling pathways.
• Coordinated Gene Expression: Using multicistronic vectors, we ensure stable, simultaneous co-expression of both the CAR and CXCR3 receptor in every T-cell.
• Relevant Functional Validation: Our specialized haptotaxis assays test T-cell migration under patient-specific TME conditions, generating predictive preclinical data.
• Established Scientific Basis: Our strategy is grounded in published evidence confirming the CXCR3-CXCL9/10 axis as critical for T-cell infiltration and checkpoint inhibitor synergy.

FAQs

Partner with Us

Creative Biolabs is your strategic partner in advancing the next generation of adoptive cell therapies. Our CXCL9/10/11-CXCR3 Chemokine-Axis Matching CAR-T Development Service provides the essential technology to overcome solid tumor barriers, delivering a T-cell product programmed for superior homing and enhanced efficacy. Ready to revolutionize your solid tumor CAR-T pipeline? Our expert team is available to discuss your specific project requirements and design a customized, data-driven strategy. Contact Our Team for More Information and to Discuss Your Project.

Reference

1. Wang, Xiaoming et al. "The role of CXCR3 and its ligands in cancer." Frontiers in Oncology vol. 12 1022688. 21 Nov. 2022. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fonc.2022.1022688